Opinion
Video
Author(s):
Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.
Video content above is prompted by the following:
NCCN Guidelines for MPN Reflect New Drugs, Focus on Clinical Trials
NCCN Guidelines for MPN Reflect New Drugs, Focus on Clinical Trials
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.